סימבקסון 40

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

SIMVASTATIN

Disponible depuis:

DEXCEL PHARMA TECHNOLOGIES LTD

Code ATC:

C10AA01

forme pharmaceutique:

קפליות

Composition:

SIMVASTATIN 40 MG

Mode d'administration:

פומי

Type d'ordonnance:

מרשם נדרש

Fabriqué par:

DEXCEL LTD, ISRAEL

Groupe thérapeutique:

SIMVASTATIN

Domaine thérapeutique:

SIMVASTATIN

indications thérapeutiques:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hype

Descriptif du produit:

Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin

Date de l'autorisation:

2020-04-30